{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:44:43Z","timestamp":1763037883146,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.03.036","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T04:59:17Z","timestamp":1682830757000},"page":"96-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-3451","authenticated-orcid":false,"given":"Atsunori","family":"Baba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sakasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kanekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.036_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2022.02.011","article-title":"SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: brief report of a TYME network safety analysis","volume":"166","author":"Giugliano","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.03.036_bib2","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1111\/ijd.15894","article-title":"Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine","volume":"60","author":"Buj\u00e1n Bonino","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2023.03.036_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/vaccines9090944","article-title":"Cutaneous adverse reactions to COVID-19 vaccines: insights from an immuno-dermatological perspective","volume":"9","author":"Niebel","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejca.2023.03.036_bib4","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/ajd.13917","article-title":"Erythema multiforme following vaccination for SARS-CoV-2: report of a case and review of the literature - secondary publication","volume":"63","author":"Kobyashi","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ejca.2023.03.036_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/jovs.2019.10.04","article-title":"Autoimmune diseases associated with thymoma","volume":"6","author":"Yano","year":"2020","journal-title":"J Vis Surg"},{"key":"10.1016\/j.ejca.2023.03.036_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/ijerph20010467","article-title":"COVID-19 vaccination and late-onset myasthenia gravis: a new case report and review of the literature","volume":"20","author":"Virgilio","year":"2022","journal-title":"Int J Environ Res Public Health"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:05Z","timestamp":1760733665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":6,"alternative-id":["S0959804923001727"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.02.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}